| Melody Hu, MD | |
|
100 Arrandale Blvd Ste 103, Exton, PA 19341 | |
| (844) 365-7246 | |
| (844) 516-0080 |
| Full Name | Melody Hu |
|---|---|
| Gender | Female |
| Speciality | Pain Management |
| Experience | 21 Years |
| Location | 100 Arrandale Blvd Ste 103, Exton, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982744769 | NPI | - | NPPES |
| 102411278 | Medicaid | PA |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Center For Interventional Pain Spine Llc | 6507040078 | 28 |
News Archive
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that it has issued $6M in convertible notes and warrants to its Series A investors bringing the total investment to date to $55M. All current investors, including Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures, Pappas Ventures and MC Life Sciences participated in the securities offering.
The four Chief Medical Officers will provide further advice on the COVID-19 vaccination of young people aged 12 to 15 with COVID-19 vaccines following the advice of the independent Joint Committee on Vaccination and Immunisation.
A study recently conducted by US Oncology and Aetna finds that evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes. The study, which compared patients treated with evidence-based guidelines (also known as ‘on pathway') to those treated with non-evidence-based guidelines (also known as ‘off pathway'), was published in the peer-reviewed Journal of Oncology Practice.
One of the most innovative biotechnologies of the last decade has recently been developed. SINEUP allows scientists, for the first time, to target individual genes in cells to knockup, or increase, the amount of protein they make. The technique will improve Protein manufacture, analyse the function of genes and engineer improved cell function.
A new study from the University of New Hampshire finds that U.S. children are routinely exposed to even more violence and abuse than has been previously recognized, with nearly half experiencing a physical assault in the study year.
› Verified 5 days ago
| Entity Name | Society Hill Anesthesia Consultants Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427003219 PECOS PAC ID: 5991617292 Enrollment ID: O20031119000358 |
News Archive
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that it has issued $6M in convertible notes and warrants to its Series A investors bringing the total investment to date to $55M. All current investors, including Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures, Pappas Ventures and MC Life Sciences participated in the securities offering.
The four Chief Medical Officers will provide further advice on the COVID-19 vaccination of young people aged 12 to 15 with COVID-19 vaccines following the advice of the independent Joint Committee on Vaccination and Immunisation.
A study recently conducted by US Oncology and Aetna finds that evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes. The study, which compared patients treated with evidence-based guidelines (also known as ‘on pathway') to those treated with non-evidence-based guidelines (also known as ‘off pathway'), was published in the peer-reviewed Journal of Oncology Practice.
One of the most innovative biotechnologies of the last decade has recently been developed. SINEUP allows scientists, for the first time, to target individual genes in cells to knockup, or increase, the amount of protein they make. The technique will improve Protein manufacture, analyse the function of genes and engineer improved cell function.
A new study from the University of New Hampshire finds that U.S. children are routinely exposed to even more violence and abuse than has been previously recognized, with nearly half experiencing a physical assault in the study year.
› Verified 5 days ago
| Entity Name | Schuylkill Internal Medicine Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912192337 PECOS PAC ID: 4183704554 Enrollment ID: O20080110000532 |
News Archive
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that it has issued $6M in convertible notes and warrants to its Series A investors bringing the total investment to date to $55M. All current investors, including Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures, Pappas Ventures and MC Life Sciences participated in the securities offering.
The four Chief Medical Officers will provide further advice on the COVID-19 vaccination of young people aged 12 to 15 with COVID-19 vaccines following the advice of the independent Joint Committee on Vaccination and Immunisation.
A study recently conducted by US Oncology and Aetna finds that evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes. The study, which compared patients treated with evidence-based guidelines (also known as ‘on pathway') to those treated with non-evidence-based guidelines (also known as ‘off pathway'), was published in the peer-reviewed Journal of Oncology Practice.
One of the most innovative biotechnologies of the last decade has recently been developed. SINEUP allows scientists, for the first time, to target individual genes in cells to knockup, or increase, the amount of protein they make. The technique will improve Protein manufacture, analyse the function of genes and engineer improved cell function.
A new study from the University of New Hampshire finds that U.S. children are routinely exposed to even more violence and abuse than has been previously recognized, with nearly half experiencing a physical assault in the study year.
› Verified 5 days ago
| Entity Name | Center For Interventional Pain Spine Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144527003 PECOS PAC ID: 6507040078 Enrollment ID: O20110407000057 |
News Archive
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that it has issued $6M in convertible notes and warrants to its Series A investors bringing the total investment to date to $55M. All current investors, including Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures, Pappas Ventures and MC Life Sciences participated in the securities offering.
The four Chief Medical Officers will provide further advice on the COVID-19 vaccination of young people aged 12 to 15 with COVID-19 vaccines following the advice of the independent Joint Committee on Vaccination and Immunisation.
A study recently conducted by US Oncology and Aetna finds that evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes. The study, which compared patients treated with evidence-based guidelines (also known as ‘on pathway') to those treated with non-evidence-based guidelines (also known as ‘off pathway'), was published in the peer-reviewed Journal of Oncology Practice.
One of the most innovative biotechnologies of the last decade has recently been developed. SINEUP allows scientists, for the first time, to target individual genes in cells to knockup, or increase, the amount of protein they make. The technique will improve Protein manufacture, analyse the function of genes and engineer improved cell function.
A new study from the University of New Hampshire finds that U.S. children are routinely exposed to even more violence and abuse than has been previously recognized, with nearly half experiencing a physical assault in the study year.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melody Hu, MD 223 Wilmington W Chester Pike Ste 214, Chadds Ford, PA 19317-9007 Ph: (844) 365-7246 | Melody Hu, MD 100 Arrandale Blvd Ste 103, Exton, PA 19341 Ph: (844) 365-7246 |
News Archive
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that it has issued $6M in convertible notes and warrants to its Series A investors bringing the total investment to date to $55M. All current investors, including Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures, Pappas Ventures and MC Life Sciences participated in the securities offering.
The four Chief Medical Officers will provide further advice on the COVID-19 vaccination of young people aged 12 to 15 with COVID-19 vaccines following the advice of the independent Joint Committee on Vaccination and Immunisation.
A study recently conducted by US Oncology and Aetna finds that evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes. The study, which compared patients treated with evidence-based guidelines (also known as ‘on pathway') to those treated with non-evidence-based guidelines (also known as ‘off pathway'), was published in the peer-reviewed Journal of Oncology Practice.
One of the most innovative biotechnologies of the last decade has recently been developed. SINEUP allows scientists, for the first time, to target individual genes in cells to knockup, or increase, the amount of protein they make. The technique will improve Protein manufacture, analyse the function of genes and engineer improved cell function.
A new study from the University of New Hampshire finds that U.S. children are routinely exposed to even more violence and abuse than has been previously recognized, with nearly half experiencing a physical assault in the study year.
› Verified 5 days ago